A randomized controlled trial of two methods of oxytocin infusion administration in prevention of blood loss at caesarean sectio
Not Applicable
Completed
- Conditions
- Pregnancy and Childbirth
- Registration Number
- PACTR201909775190644
- Lead Sponsor
- Aduloju Olusola Peter
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 210
Inclusion Criteria
pregnant women with a single fetus at term >37 weeks of gestational age, with American Society of Anesthesiology (ASA) physical status I or II
Exclusion Criteria
Women at high risk for
uterine atony such as anemia (Hb <8 g/dL), multiple gestation, polyhydramnios
placenta previa,
fetal macrosomia
two or more previous CS
preeclampsia,
current or previous history of heart disease, liver, renal disorders or known coagulopathy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie oxytocin's efficacy in preventing postpartum hemorrhage during caesarean sections?
How does early oxytocin infusion compare to standard uterotonic agents in reducing blood loss during cesarean deliveries?
Are there specific biomarkers that predict optimal response to early oxytocin administration in high-risk pregnancies?
What adverse events are associated with continuous oxytocin infusion versus bolus administration during caesarean sections?
How does oxytocin administration timing impact hemostatic parameters in women with placenta previa undergoing caesarean section?